Since the 1990s, the biotechnology industry has risen by leaps and bounds. The sector has produced medical titans such as Gilead Sciences, Amgen, Biogen Idec, and Celgene. At the opposite end of the spectrum are hundreds of tiny, active biotech firms, many of which are interested in sectors of the medical business such as drug development, genomics, or proteomics, while others are involved in bioremediation, biofuels, and food products. There have also been significant product debuts in biopharma medications.
The following are some of the most often utilised biotechnology medical goods that have lately been introduced:
· Humira, a drug manufactured by AbbVie that is used to treat arthritis, psoriasis, and Crohn's disease.
· Roche's Rituxan, which is used to suppress tumour development in a variety of cancers.
· Enbrel, a drug developed by Amgen and Pfizer, is used to treat a variety of autoimmune illnesses.
Discover the Complete Blog- https://bit.ly/3zgyE0r
